Modelling upper respiratory viral load dynamics of SARS-CoV-2

Joseph D. Challenger^{1*}, Cher Y. Foo², Yue Wu³, Ada W. C. Yan⁴, Mahdi Moradi Marjaneh⁵, Felicity Liew⁶, Ryan S. Thwaites⁶, Lucy C. Okell¹, Aubrey J. Cunnington^{5,7}

1. Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom

2. Faculty of Medicine, Imperial College London, London, United Kingdom

3. School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom

4. Department of Infectious Disease, Imperial College London, London, United Kingdom

5. Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, United Kingdom

6. National Heart and Lung Institute, Imperial College London, United Kingdom

7. Centre for Paediatrics and Child Health, Imperial College London, United Kingdom

*Corresponding author

SUPPLEMENTARY MATERIALS

This document contains:

- 1. Supplementary Tables 1-4
- 2. Supplementary Figures 1-7

All references numbered as per the main text

| Title | Journal | D.O.I. | Date of request |
|--|---|---|------------------|
| Temporal dynamics in viral shedding and transmissibility | | | |
| of COVID-19 | Nature Medicine https://doi.org/10.1038/s41591-020-0869-5 | | May 26th 2020 |
| Temporal profiles of viral load in posterior | | | |
| oropharyngeal saliva samples and serum antibody | | | |
| responses during infection by SARS-CoV-2: an | | | |
| observational cohort study | Lancet ID | https://doi.org/10.1016/S1473-3099(20)30196-1 | Oct 22nd 2020 |
| Prolonged presence of SARS-CoV-2 viral RNA in faecal | | | |
| samples | Lancet G Hep | https://doi.org/10.1016/S2468-1253(20)30083-2 | June 1st 2020 |
| Clinical Course and Outcomes of Patients with Severe | | | |
| Acute Respiratory Syndrome Coronavirus 2 Infection: a | | | |
| Preliminary Report of the First 28 Patients from the | | | |
| Korean Cohort Study on COVID-19 | J Korean Med Sci | https://doi.org/10.3346/jkms.2020.35.e142 | June 1st 2020 |
| Viral Kinetics and Antibody Responses in Patients with | | | |
| COVID-19 | medRxiv | https://doi.org/10.1101/2020.03.24.20042382 | May 26th 2020 |
| Different longitudinal patterns of nucleic acid and | | | |
| serology testing results based on disease severity of | Emerging Microbes & | | |
| COVID-19 patients | Infections | https://doi.org/10.1080/22221751.2020.1756699 | June 1st 2020 |
| The presence of SARS-CoV-2 RNA in the feces of COVID- | Journal of Medical | | |
| 19 patients | Virology | https://doi.org/10.1002/jmv.25825 | Oct 21st 2020 |
| Chronological Changes of Viral Shedding in Adult | Clinical Infectious | | |
| Inpatients with COVID- 19 in Wuhan, China Diseases | | https://doi.org/10.1093/cid/ciaa631 | June 1st 2020 |
| Correlation between viral RNA shedding and serum | Clinical Microbiology and | | |
| antibodies in COVID-19 patients | Infection | https://doi.org/10.1016/j.cmi.2020.05.022 | June 1st 2020 |
| Viral load dynamics and disease severity in patients | | | |
| infected with SARS-CoV-2 in Zhejiang province, China, | | | |
| January-March 2020: retrospective cohort study | BMJ | https://doi.org/10.1136/bmj.m1443 | June 1st 2020 |
| Clinical features and dynamics of viral load in imported | International Journal of | | |
| and non-imported patients with COVID-19 | Infectious Diseases | https://doi.org/10.1016/j.ijid.2020.03.022 | June 1st 2020 |
| Antibody responses to SARS-CoV-2 in patients of novel | Clinical Infectious | | |
| coronavirus disease 2019 | Diseases | https://doi.org/10.1093/cid/ciaa344 | August 20th 2020 |
| Phenotype of SARS-CoV-2-specific T-cells in COVID-19 | | | |
| patients with acute respiratory distress syndrome | medRxiv | https://doi.org/10.1101/2020.04.11.20062349 | June 16th 2020 |
| Shedding of infectious virus in hospitalized patients with | | | |
| coronavirus disease-2019 (COVID-19): duration and key | | | |
| determinants | medRxiv | https://doi.org/10.1101/2020.06.08.20125310 | June 16th 2020 |

| SARS-CoV-2 viral load predicts COVID-19 mortality | Lancet Resp Med | https://doi.org/10.1016/S2213-2600(20)30354-4 | August 14th 2020 |
|---|--------------------------|--|------------------|
| Duration of viral shedding in asymptomatic or mild | | | |
| cases of novel coronavirus disease 2019 (COVID-19) | | | |
| from a cruise ship: A single-hospital experience in | International Journal of | | |
| Tokyo, Japan | Infectious Diseases | https://doi.org/10.1016/j.ijid.2020.06.020 | August 20th 2020 |
| Relative COVID-19 viral persistence and antibody | | | |
| kinetics | MedRxiv | https://doi.org/10.1101/2020.07.01.20143917 | August 19th 2020 |
| Kinetics of viral load and antibody response in relation | The Journal of Clinical | | |
| to COVID-19 severity | Investigation | https://doi.org/10.1172/JCI138759 | August 20th |
| SARS-CoV-2 RT-PCR profile in 298 Indian COVID-19 | | | |
| patients: a retrospective observational study | MedRxiv | https://doi.org/10.1101/2020.06.19.20135905 | August 19th 2020 |
| Viral load dynamics in transmissible symptomatic | | | |
| patients with COVID-19 | MedRxiv | https://doi.org/10.1101/2020.06.02.20120014 | August 19th 2020 |
| Clinical Course and Molecular Viral Shedding Among | | | |
| Asymptomatic and Symptomatic Patients With SARS- | | | |
| CoV-2 Infection in a Community Treatment Center in the | | | |
| Republic of Korea | JAMA | https://doi.org/10.1001/jamainternmed.2020.3862 | August 19th 2020 |
| Duration of infectiousness and correlation with RT-PCR | | | |
| cycle threshold values in cases of COVID-19, England, | | https://doi.org/10.2807/1560- | |
| January to May 2020 | Eurosurvellance | 7917.ES.2020.25.32.2001483 | August 19th 2020 |
| Clinical Characteristics and Viral RNA Detection in | | | |
| Children With Coronavirus Disease 2019 in the Republic | | | |
| of Korea | JAMA Pediatr | https://doi.org/10.1001/jamapediatrics.2020.3988 | Sept 4th 2020 |
| Temporal profile and determinants of viral shedding and | | | |
| of viral clearance confirmation on nasopharyngeal | | | |
| swabs from SARS-CoV-2-positive subjects: a population- | | | |
| based prospective cohort study in Reggio Emilia, Italy | BMJ Open | http://dx.doi.org/10.1136/bmjopen-2020-040380 | Sept 9th 2020 |
| Viral Dynamics and Immune Correlates of Coronavirus | Clinical Infectious | | |
| Disease 2019 (COVID-19) Severity | Diseases | https://doi.org/10.1093/cid/ciaa1280 | Oct 16th 2020 |
| Clinical Performance of SARS-CoV-2 Molecular Tests | J Clin Microbiology | https://doi.org/10.1128/JCM.00995-20 | Oct 21st 2020 |
| Viral dynamics in mild and severe cases of COVID-19 | Lancet ID | https://doi.org/10.1016/S1473-3099(20)30232-2 | Oct 22nd 2020 |
| Clinical and epidemiological features of COVID-19 family | | | |
| clusters in Beijing, China | Journal of Infection | https://doi.org/10.1016/j.jinf.2020.04.018 | Oct 22nd 2020 |
| Clinical and epidemiological features of 36 children with | | | |
| coronavirus disease 2019 (COVID-19) in Zhejiang, China: | | | |
| an observational cohort study | Lancet ID | https://doi.org/10.1016/S1473-3099(20)30198-5 | Oct 22nd 2020 |

| Viral loads in throat and anal swabs in children infected | Emerging Microbes & | | |
|---|---------------------------|---|---------------|
| with SARS-CoV-2 | Infections | https://doi.org/10.1080/22221751.2020.1771219 | Oct 22nd 2020 |
| Factors of Severity in Patients with COVID-19: | | | |
| Cytokine/Chemokine Concentrations, Viral Load, and | | | |
| Antibody Responses | АЈТМН | https://doi.org/10.4269/ajtmh.20-1110 | Nov 26th 2020 |
| | Clinical Microbiology and | | |
| The kinetics of viral load and antibodies to SARS-CoV-2 | Infection | https://doi.org/10.1016/j.cmi.2020.08.043 | Nov 26th 2020 |
| The Correlation Between Clinical Features and Viral RNA | Open Forum Infectious | | |
| Shedding in Outpatients With COVID-19 | Diseases | https://doi.org/10.1093/ofid/ofaa331 | Nov 26th 2020 |
| Molecular and serological characterization of SARS-CoV- | | | |
| 2 infection among COVID-19 patients | Virology | https://doi.org/10.1016/j.virol.2020.09.008 | Nov 26th 2020 |

Supplementary Table 1: Summary of studies which were identified during the literature search but did not provide data when the corresponding authors were contacted.

| Study | Reference | No. of Patients | Country | Healthcare setting | Recruitment period | Antiviral treatment, n (%) | | Immunomodulatory trea | tment, n(%) | |
|-------|--|--------------------|-------------|--|-------------------------|---|------------------------------|-----------------------|-------------|--|
| 1 | Kim JY <i>et al.</i> , J Korean Med Sci, 2020 [42] | 2 | Korea | Hospital | January 2020 | Lopinavir/Ritonavir | 2 (100) | 0 | 0 | |
| 2 | Lui G <i>et al</i> ., J Infect, 2020 [53] | 11 | Hong Kong | Multicentre, Hospital | February 2020 | Lopinavir/Ritonavir Ribavirin Beta-interferon | 11 (100) 8 (73) 5 (56) | Hydrocortisone | 1 (9) | |
| 3 | Scott S <i>et al.</i> , Clin Infect Dis, 2020 [54] | 1 | USA | Community | January 2020 | None used | None used | | None used | |
| 4 | Kim SE, Int J Infect Dis, 2020 [55] | 3 | Korea | Tertiary Hospital | February – April 2020 | Lopinavir/Ritonavir 1 (33) | | None used | | |
| 5 | Gautret P <i>et al.</i> , Int J Antimicrob Agents, 2020 [56] | 19 | France | Tertiary Hospital | March 2020 | None used | | Hydroxychloroquine | 18 (95) | |
| 6 | Young B <i>et al.</i> , JAMA, 2020 [57] | 18 | Singapore | Multicentre, Tertiary Hospital | January – February 2020 | Lopinavir/Ritonavir 5 (28) | | None used | | |
| 7 | The COVID–19 Investigation team, Nat Med, 2020 [58] | 12 | USA | Multicentre, Community and Hospital | January 2020 | Remdesivir | 3 (25) | Corticosteroids | 2 (17) | |
| 8 | Wölfel R <i>et al.</i> , Nature, 2020 [59] | 9 | Germany | Hospital | January 2020 | Not reported | | Not reported | | |
| 9 | Vetter P <i>et al.</i> , mSphere, 2020 [60] | 5 | Switzerland | Hospital | February 2020 | Lopinavir/Ritonavir | 1 (20) | None used | | |
| 10 | Lavezzo E <i>et al.</i> , Nature, 2020 [43] | 37 | Italy | Community and Hospital | February – March 2020 | Not reported | | Not reported | · | |
| 11 | Xu Y <i>et al.,</i> Nat Med, 2020 [61] | 6 | China | Paediatric cohort, Tertiary Hospital | January – February 2020 | Alpha-interferon | 6 (100) | IVIG | 1 (17) | |
| 12 | Shrestha N <i>et al.</i> , Clin Infect Dis, 2020 [62] | 230 | USA | Healthcare worker cohort, non– hospitalized | March – April 2020 | None used | | None used | | |
| 13 | Fajnzylber J <i>et al.</i> , Nat Commun, 2020 [63] | 64 | USA | Multicentre, Tertiary Hospital | NK | Remdesivir | 16 (25) | None used | | |
| 14 | Yilmaz A e <i>t al</i> ., J Infec Dis, 2020 [64] | 54 | Sweden | Tertiary Hospital | February – April 2020 | Not reported | | Not reported | | |
| 15 | Alsharrah <i>et al.</i> , J Med Virol, 2020 [65] | 29 | Kuwait | Paediatric cohort, Tertiary Hospital | February – April 2020 | None used | | None used | | |
| 16 | Tan A <i>et al.</i> , Cell Reports, 2020 [7] | 12 | Singapore | Tertiary Hospital | NK | Not reported | | Not reported | | |
| 17 | Salvatore PP <i>et al.</i> , Clin Infec Dis, 2020 [66] | 93 | USA | Community | March – May 2020 | None used | | None used | | |

Supplementary Table 2. Summary of antiviral and immunomodulatory treatment in the studies included in analysis.

| Parameter | Interpretation | Posterior | 95% CrI |
|-------------------------|---|-----------|---------------|
| | | Mean | |
| a ₀ | Average value of the peak log ₁₀ (VL) | 6.74 | (6.17,7.30) |
| b ₀ | Average value of the rate of decline (per day) of | -0.22 | (-0.26,-0.17) |
| | the log ₁₀ (VL) | | |
| $\sigma_{patient}[1]$ | Standard deviation of the between-patient | 1.54 | (1.26,1.85) |
| | variation in the peak log ₁₀ (VL) | | |
| $\sigma_{patient}[2]$ | Standard deviation of the between-patient | 0.15 | (0.12,0.19) |
| | variation rate of decline (per day) of the log ₁₀ (VL) | | |
| ρ_{patient} | Correlation between σ_{patient} [1] and σ_{patient} [2] | -0.86 | (-0.92,-0.76) |
| $\sigma_{study}[1]$ | Standard deviation of the between-study | 0.81 | (0.42,1.35) |
| | variation in the peak log ₁₀ (VL) | | |
| $\sigma_{study}[2]$ | Standard deviation of the between-study | 0.04 | (0.01,0.09) |
| | variation rate of decline (per day) of the $log_{10}(VL)$ | | |
| $ ho_{study}$ | Correlation between σ_{study} [1] and σ_{study} [2] | -0.18 | (-0.80,0.45) |
| σ | Standard deviation of the observed variation in | 1.08 | (1.01,1.16) |
| | log ₁₀ (VL) around the linear model | | |

Supplementary Table 3: Summary of the population-level (i.e. not study- or patient-specific) parameter values (and 95% credible intervals) obtained for the multi-level regression modelling (as displayed in Figure 2). Patient- and study-specific random effects were used for both the peak (log-transformed) viral load, and its rate of decline per day.

| Parameter | Interpretation | Posterior | 95% Crl |
|------------------|---|-----------|---------------|
| | | Mean | |
| k_a^0 | Population-level late immune response | 6.32 | (5.84-6.74) |
| σ_{kp} | Standard deviation of patient-level offset in the | 13.62 | (12.40-15.02) |
| | late immune response | | |
| σ_{ks} | Standard deviation of study-level offset in the | 0.74 | (0.49-1.04) |
| | late immune response | | |
| I _{max} | Population-level late immune response | 0.66 | (0.31-1.12) |
| σ_{Ip} | Standard deviation of patient-level offset in the | 2.81 | (2.37-3.26) |
| - | early immune response | | |
| σ_{Is} | Standard deviation of study-level offset in the | 2.85 | (1.92-4.10) |
| | early immune response | | |
| σ | Standard deviation of variation of viral load | 3.21 | (3.00-3.43) |
| | around modelled trajectory | | |

Supplementary Table 4: Summary of the population-level (i.e. not study- or patient-specific) parameter values (and 95% credible intervals) obtained for the mechanistic viral load model (Equations 6-8). Samples from k_a^0 and I_{max}^0 were used to generate the black line and dark grey shaded area in Figure 4.



Supplementary Figure 1: Standard curves relating cycle-threshold (Ct) values to viral load. Seven standard curves, identified from published studies (see Methods) are plotted. We used these standard curves to produce a model of an averaged standard curve (thicker orange line), and capture the variation observed across different studies. We only used standard curves which quantified viral load in units of viral copies per ml. Standard curves generated by drawing random samples from this model are shown by opaque, grey lines, indicating the potential variation in the standard curve.



Supplementary Figure 2: Summary of all the data collected (see Table 1 in the main text). For the studies shown in blue, viral loads have been estimated using an averaged standard curve (see Methods for details). For illustrative purposes, samples that were negative for virus are set to 1 viral copy per ml. In each panel, the lines connect samples collected from the same patient.



Supplementary Figure 3: Comparison of timing of first sample and viral load by severity. a) Timing of first viral load measurement for each patient, relative to symptom onset. Here severity indicates the maximum severity recorded for each patient, rather than the severity recorded at admission. We find that, on average, the first viral load measurement for patients with mild disease was recorded earlier than those for either patients with moderate disease, or severe disease (p-values from a two-sided Wilcoxon test). b) Quantification of the first viral load measurement for each patient, stratified by severity classification. c) Quantification of the maximum viral load. As shown in the left-hand panel, we have many more data points for mild patients early after the onset of symptoms, which is why both the first and maximum recorded viral loads are higher on average for this group. Across these studies, 421 patients had more than one sample recorded: for 60.1% of these patients, the first sample had the highest recorded viral load.



Supplementary Figure 4: Estimations of the statistical power in the regression analyses. We used simulation-based methods to estimate our power to measure an effect on the peak viral load due to severity of disease, age, or sex. We simulated datasets of the same size as the one used here for the regression analysis, containing the same level of variation between subjects and studies (Supplementary Table 3). In each set of simulations, the peak viral load was influenced by one of these 3 variables (panel (a): severity of disease; panel (b): age; panel (c): sex). In each case 1000 simulations were generated and the statistical power (black dots) calculated as the proportion of cases for which a significant effect (a fixed effect with a p value < 0.05 was deemed to show significance). The error bars show the 95% confidence intervals for each proportion calculated. In each panel, the purple, dashed line indicates 80% power. These plots suggest that we were underpowered to detect relatively small differences in viral load due to age, sex, or disease severity.



Supplementary Figure 5: Relationship between patient-specific parameters governing the immune response in the mechanistic model and disease severity. After adjusting for study (through the study-specific random effect) no significant differences were found between either the patient-specific early (panel a) or late (panel b) immune response parameters in the severity groups. This is consistent with the findings from the regression modelling. In this plot we show the posterior mean value of the subject-specific parameters.



Supplementary Figure 6: Posterior means and 95% credible intervals for the study-specific offsets in the mechanistic model. Panel (a): the parameter values for the early immune response, which influences the peak viral load. Panel (b): the parameter values for the late immune response, which governs the rate at which the viral load is cleared.

Supplementary Figure 7 (shown over the following 7 pages): Output from the mechanistic model alongside the data, for all 155 patients considered. In the heading of each panel, the first number indicates the study (studies numbered as in Table 1). The second number identifies the patient. The coloured points indicate the data: for illustrative purposes, samples that were negative for virus are set to 1 viral copy per ml. The black lines indicate the model fit for each patient (calculated from the posterior mean). The shaded area shows the 95% credible intervals for the model fit.

page 1 of 7



page 2 of 7



Days after symptom onset

page 3 of 7



page 4 of 7



page 5 of 7



page 6 of 7



Days after symptom onset

page 7 of 7

